RGS proteins: impact on the treatment of depression and anxiety.
RGS proteins: impact on the treatment of depression and anxiety.
复制标题
RGS 蛋白：对抑郁和焦虑治疗的影响。
DOI：
10.1017/s1461145711002008
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Muma,NancyA
中科院分区：
文献类型：
--
作者：
Muma,NancyA
Regulators of G protein signalling (RGS) proteins were first found to limit heterotrimer G protein signalling by accelerating the hydrolysis of GTP-bound to Gα subunits, thereby terminating receptor pathway signalling. Subsequently, RGS proteins have been found to act as scaffolding proteins, to interact directly and selectively to G protein-coupled receptors (GPCRs) and to act as effector modulators (Ghavami et al. 2004; McCoy & Hepler, 2009). Through all of these interactions, RGS proteins act to negatively regulate signalling pathways. The selective interactions that occur among GPCRs, G proteins and RGS proteins provide an opportunity for more selective drug targeting to a specific complex of these proteins,(McCoy & Hepler, 2009; Shankaranarayanan et al. 2008) rather than the traditional approach of targeting GPCRs or more recent proposals for targeting RGS proteins. Targeting select GPCR/G protein/RGS complexes may prove useful for improving the treatment of depression.Although major depression is a common disorder, treatment approaches for depression are woefully inadequate (Insel & Wang, 2009). Approximately one in six people in the USA suffer from major depressive disorder and individuals have a 16.2% lifetime prevalence for depression (Kessler et al. 2003). There are several classes of medications which are useful in the treatment of depression including selective serotonin reuptake inhibitors (SSRIs) and mixed norepinephrine/serotonin reuptake inhibitors. In fact, from recently published data on the top prescription drugs of 2010, two of these reuptake inhibitor anti-
